Commentary · 21 Feb 2026
Conference abstractPublished 16 Jul 2018
Lovastatin inhibits Triple - Negative Breast Cancer stem cells through lysine crotonylation and succinylation of ribosomal and cytoskeletal proteins
Hunan Normal University Medical College, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Triple-Negative Breast Cancer (TNBC) is the most difficult-to-treat breast cancer subtype. Statins have gained increasing interest as anti-cancer drugs in preclinical investigations. However, clinical trials with statins have yielded inconsistent results. We demonstrated that lovastatin inhibited stemness properties, enhanced chemosensitivity and induced autophagy/ apoptosis in Cancer Stem Cells (CSCs) derived from TNBC cells. In a mouse model of orthotopic tumor growth, Lovastatin inhibited tumor burden, CSC markers, angiogenesis and tumor-stromal interaction and induced cell death in TNBC CSCs. Similar results were not observed in non-TNBC cells in vitro or in vivo. Using TMT labeling followed by high-resolution LC-MS/MS, we performed global profiling of the proteome and lysine acylome in MDA-MB-231 (TNBC) vs. MDA-MB-453 (non-TNBC) CSCs. GO pathway analysis revealed significant enrichment in lysine crotonylome and succinylome but not in the proteome in MDA-MB-231 CSCs treated with lovastatin, suggesting that lysine acylation but not proteomic alteration was the preferred mechanism of lovastatinâ??s inhibitory effects on TNBC CSCs. Specifically, acylation enrichment was found in two functional categories, i.e., ribosomal constituents and cytoskeletal protein binding, both involved in stress response. Enhanced ribosome biogenesis was confirmed by increased staining of the argyrophilic nucleolar organizer region in Lovastatin-treated CSCs. Actin cytoskeleton disruption was confirmed by nuclear/perinuclear translocation of F-actin in Lovastatin-treated CSCs. Our data suggest that Lovastatin-induced lysine acylation mediates stress response which results in disruption of protein homeostasis and eventual cell death of TNBC CSCs. These findings support the use of lovastatin as a candidate targeted drug for the precision therapy of TNBC patients.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Xiyun Deng”
- BylineArticles whose byline prints “Guangchun He”
- BylineArticles whose byline prints “Hui Yao”
- BylineArticles whose byline prints “Chao Chen”
- BylineArticles whose byline prints “Lu Lu”
- BylineArticles whose byline prints “Shichao Yan”
- BylineArticles whose byline prints “Huimei Yi”
